Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor

被引:0
|
作者
Eric D. Tetzlaff
Jaffer A. Ajani
机构
[1] The University of Texas M.D. Anderson Cancer Center,Department of Gastrointestinal Oncology and Digestive Systems
来源
关键词
Carcinoid; chromogranin A; interferon alpha; octreotide; oxaliplatin;
D O I
10.1385/IJGC:36:1:055
中图分类号
学科分类号
摘要
Carcinoid tumors are rare and often resistant to chemotherapy agents. Although a slow-growing tumor, patients can have significant morbidity associated with carcinoid syndrome and patients will often die as a result of tumor progression. We report the first case of a patient with a metastatic carcinoid tumor to respond to an oxaliplatin-based regimen. Further studies are needed to validate this observation.
引用
收藏
页码:55 / 58
页数:3
相关论文
共 50 条
  • [21] Splenomegaly During Oxaliplatin-based Chemotherapy for Colorectal Carcinoma
    Jung, Eun-Joo
    Ryu, Chun-Geun
    Kim, Gangmi
    Kim, Su Ran
    Park, Hee Sun
    Kim, Young Jun
    Hwang, Dae-Yong
    ANTICANCER RESEARCH, 2012, 32 (08) : 3357 - 3362
  • [22] Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy
    Seo, An Na
    Kim, Haeryoung
    CLINICAL AND MOLECULAR HEPATOLOGY, 2014, 20 (01) : 81 - 84
  • [23] Oxaliplatin-based chemotherapy inpatients with advanced pancreatic cancer
    Vattemi, E.
    Franchi, R.
    Pedersini, R.
    Tansini, G.
    Baier, S.
    Costa, P.
    Signaroldi, A.
    Zanaletti, F.
    Sbalzarini, G.
    Graiff, C.
    ANNALS OF ONCOLOGY, 2006, 17 : 34 - 34
  • [24] Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy
    Berretta, M
    Taibi, R
    Bearz, A
    La Mura, N
    Berretta, S
    Tirelli, U
    Frustaci, S
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (06) : 595 - 598
  • [25] COMBINATION CHEMOTHERAPY TRIALS FOR METASTATIC CARCINOID TUMOR
    MOERTEL, CG
    HANLEY, JA
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 322 - 322
  • [26] DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy
    Kai-yuan Teng
    Miao-zhen Qiu
    Zhuang-hua Li
    Hui-yan Luo
    Zhao-lei Zeng
    Rong-zhen Luo
    Hui-zhong Zhang
    Zhi-qiang Wang
    Yu-hong Li
    Rui-hua Xu
    Journal of Translational Medicine, 8
  • [27] Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Tatsumi, Shigenobu
    Matsuoka, Hiroshi
    Hashimoto, Yumi
    Hatta, Kohei
    Maeda, Kotaro
    Kamoshida, Shingo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (01): : 204 - 212
  • [28] DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy
    Teng, Kai-yuan
    Qiu, Miao-zhen
    Li, Zhuang-hua
    Luo, Hui-yan
    Zeng, Zhao-lei
    Luo, Rong-zhen
    Zhang, Hui-zhong
    Wang, Zhi-qiang
    Li, Yu-hong
    Xu, Rui-hua
    JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [29] Excellent Treatment Response of an Aggressive Primary Duodenal Neuroendocrine Carcinoma to Oxaliplatin-Based Chemotherapy
    Sigale, Stephanie
    Zollars, Tai
    Ramachandran, Shreya
    Burns, Carson R.
    Ramachandran, Preethi
    Kathirvelu, Balachandar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S2154 - S2154
  • [30] MIR-133A IS A PREDICTIVE BIOMARKER IN PATIENTS WITH METASTATIC COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED CHEMOTHERAPY
    Ng, Simon S.
    Dong, Yujuan
    Leung, Wing Wa
    Ma, Brigette B.
    To, Ka Fai
    Sung, Joseph J.
    Yu, Jun
    GASTROENTEROLOGY, 2018, 154 (06) : S88 - S88